Skip to main content


Media Contacts:


Polina Miklush
Mobile: +1 908 608 7170

Seqirus news releases

Seqirus news releases

Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans
23 Mar 2021

Health Canada’s Approval of FOCLIVIA® (An Adjuvanted, Egg-Based A Strain H5N1 Pandemic Influenza Vaccine) Meets Key Requirement as Pandemic Partner

Seqirus Presents Key Insights on Influenza Vaccines at the Canadian Immunization Conference 2020
02 Dec 2020

Absolute Efficacy of Cell-Based Influenza Vaccines in Children Aged 2 to 18 Years, Impact of COVID-19 on Canadians’ Views of Influenza, Among Data Being Presented

COVID-19 Update
02 Apr 2020

Safeguarding our people and communities remains our top priority.

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
11 Dec 2019

/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains1.